The use of natriuretic peptide to screen for stage B heart failure based on echocardiogram among cancer survivors
European Heart Journal – Cardio-Oncology · 2026
DOI: 10.1093/ehjco/aabag003 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal – Cardio-Oncology, 2026. Verfasst von Cheng Hwee Soh und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background and Aims Heart failure is a progressive disorder that can be identified at earlier stage, also known as stage B heart failure (SBHF). While N-terminal pro-B-type natriuretic peptide (NT-proBNP) was shown to be a key biomarker, its screening performance among cancer survivors remains uncertain. This study aimed to identify the performance of NT-proBNP in identifying SBHF, encompassing both structural and functional abnormalities, in survivors.
Methods
Survivors ≥5 years post cancer therapy and with ≥1 cardiovascular risk factor were recruited. SBHF was defined as diastolic dysfunction (E/e’ >13 with left atrial volume index >34ml/m2), reduced global longitudinal strain (GLS), reduced left ventricular ejection fraction (LVEF) or left ventricular hypertrophy (LVH). In this predominantly cross-sectional analysis, we analysed the association between NT-proBNP with SBHF, adjusting for age, sex, diabetes, blood pressure and antihypertensive medication. Area under the curve (AUC) was used to assess discrimination of NT-proBNP for SBHF and various thresholds were applied.
Results
Among 441 long-term survivors (mean age 65.0±8.9 years, 85.7% female), elevated NT-proBNP levels were associated with SBHF (OR 1.63 [95%CI 1.20-2.22], p=0.002) and reduced GLS (adjusted OR 1.81 [1.32-2.50], p<0.001), whereas associations with diastolic dysfunction, LVH, and reduced LVEF were not significant. Discriminatory performances of NT-proBNP for SBHF and its subtypes were poor, with AUCs ranging from 0.60 to 0.64. The conventional threshold (>125pg/mL) demonstrated inadequate sensitivity (42.7%) and specificity (68.2%). Lower thresholds (>55pg/mL) improved sensitivity (82.3%) but reduced specificity (30.3%).
Conclusion
The poor sensitivity of NT-proBNP for SBHF limits its effectiveness as a standalone screening tool.
Zitieren
APA
Soh, C. H., Wong, J., Zhu, G., Azad, A., Whitmore, K., & Marwick, T. H. (2026). The use of natriuretic peptide to screen for stage B heart failure based on echocardiogram among cancer survivors. European Heart Journal – Cardio-Oncology. https://doi.org/10.1093/ehjco/aabag003
Vancouver
Soh CH, Wong J, Zhu G, Azad A, Whitmore K, Marwick TH. The use of natriuretic peptide to screen for stage B heart failure based on echocardiogram among cancer survivors. European Heart Journal – Cardio-Oncology. 2026. doi:10.1093/ehjco/aabag003
BibTeX
@article{Soh2026,
author = {Soh, Cheng Hwee and Wong, Joshua and Zhu, Guangli and Azad, Atro and Whitmore, Kristyn and Marwick, Thomas H},
title = {The use of natriuretic peptide to screen for stage B heart failure based on echocardiogram among cancer survivors},
journal = {European Heart Journal – Cardio-Oncology},
year = {2026},
doi = {10.1093/ehjco/aabag003}
}
EUVIMED